LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Unlocking Growth, Navigating Financial Triumphs And Market Expansion In The Pharmaceutical Arena
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$917.97 |
52 Week High | US$972.53 |
52 Week Low | US$547.61 |
Beta | 0.42 |
11 Month Change | -0.38% |
3 Month Change | 6.00% |
1 Year Change | 57.01% |
33 Year Change | 276.60% |
5 Year Change | 733.00% |
Change since IPO | 32,584.33% |
Recent News & Updates
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Recent updates
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)
Aug 12Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic
Aug 04Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
Jul 25A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)
Jul 16Wall Street Lunch: Merger Monday In All Its Glory
Jul 085 Reasons Eli Lilly Just Keeps Rising
Jun 30Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)
Jun 24Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Jun 17Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
Jun 11These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well
Jun 10Eli Lilly's Growth And Challenges: A Cautious Buy
Jun 01Shareholder Returns
LLY | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.5% | 0.2% | 0.8% |
1Y | 57.0% | 23.5% | 38.4% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 23.5% over the past year.
Return vs Market: LLY exceeded the US Market which returned 38.4% over the past year.
Price Volatility
LLY volatility | |
---|---|
LLY Average Weekly Movement | 4.9% |
Pharmaceuticals Industry Average Movement | 9.4% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LLY's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
LLY fundamental statistics | |
---|---|
Market cap | US$826.56b |
Earnings (TTM) | US$7.34b |
Revenue (TTM) | US$38.92b |
112.6x
P/E Ratio21.2x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LLY income statement (TTM) | |
---|---|
Revenue | US$38.92b |
Cost of Revenue | US$7.49b |
Gross Profit | US$31.43b |
Other Expenses | US$24.09b |
Earnings | US$7.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
Earnings per share (EPS) | 8.15 |
Gross Margin | 80.75% |
Net Profit Margin | 18.86% |
Debt/Equity Ratio | 212.9% |
How did LLY perform over the long term?
See historical performance and comparison